Histogen Inc. (NASDAQ: HSTO) announces its participation as a presenting company at BIO Digital 2020, scheduled from June 8-12, 2020. This follows the completion of its merger with Conatus Pharmaceuticals. Currently, Histogen is conducting a Phase 1b/2a clinical trial for its lead product, HST 001, targeting male pattern hair loss. The company also anticipates advancements in HST 002, a novel dermal filler, and HST 003 for joint cartilage regeneration. Presentation details will be available on-demand post-event.
Histogen Inc. (NASDAQ: HSTO) has initiated its Phase 1b/2a clinical trial for HST 001, targeting androgenic alopecia in men. This study, enrolling 36 subjects, will assess safety and efficacy indicators such as hair count and density. With dosing at weeks 0, 6, and 12, top-line results are expected by Q4 2020. HST 001 aims to offer a transformative treatment by promoting new hair growth rather than just reducing hair loss, utilizing enriched growth factors. This milestone follows Histogen's recent Nasdaq listing.